ELVN Enliven Therapeutics
- 22.470
- -0.400-1.75%
- 22.470
- 0.0000.00%
Enliven Therapeutics News
Clear Street Launches Healthcare & Biotechnology Equity Research
We're Hopeful That Enliven Therapeutics (NASDAQ:ELVN) Will Use Its Cash Wisely
BTIG Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $42
Enliven Therapeutics' ELVN-001: Navigating Competitive Challenges and Opportunities in the CML Market
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38
JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $36
Strong Buy Recommendation for Enliven Therapeutics: Promising Efficacy and Strategic Positioning in CML Market
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $36 to $40
Express News | Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40
Enliven Therapeutics Reports Q3 Results and Clinical Progress
Express News | Enliven Therapeutics Inc : Jefferies Raises Target Price to $33 From $32
Enliven Therapeutics: Promising Clinical Developments and Robust Financial Position Justify Buy Rating
Express News | Enliven Therapeutics Inc: Current Cash, Cash Equivalents and Marketable Securities Expected to Provide Cash Runway Into Late 2026
Enliven Therapeutics | 10-Q: Q3 2024 Earnings Report
Enliven Therapeutics | 8-K: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Express News | Enliven Therapeutics Q3 2024 GAAP EPS $(0.48) Beats $(0.49) Estimate
Express News | Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Express News | Enliven Therapeutics Q3 Income From Operations USD -27.068 Million
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Enliven Therapeutics Price Target Announced at $36.00/Share by Jones Trading
No Data